Market Overview

JPMorgan Downgrades Cabot Corp. To Neutral


JPMorgan’s Jeffrey J. Zekauskas downgraded the rating on Cabot Corp (NYSE: CBT) from Overweight to Neutral, while raising the price target from $45 to $47.

Share Price Up

The stock has appreciated 18 percent year to date, as compared to a 1 percent decrease in the S&P average.

However, Zekauskas explained that this recent sharp rise in Cabot’s share price was unlikely to be indicative of any “fundamental positive changes in Cabot’s business conditions.”

In fact, the analyst vies this change “as consistent with the share price performances of many smaller-capitalization Chemical stocks in a, now, risk-on market environment.”

Related Link: Cabot Corporation Announces Resignation Of Prevost And Appointment Of Keohane As CEO

Estimates Revised

The EPS estimate for FY2016 has been raised from $3.05 to $3.15, to reflect higher expectations for volumes in the Reinforcement Materials business, along with a better outlook for the Purifications Solutions and Specialty Fluids businesses in 2HFY16.

The EPS estimates for FY2017 and FY2018 have also been raised due to the higher base for FY2016.

The free cash flow per share estimate for 2016 has been lowered from $3.30 to $2.86 to reflect a decrease in expectations for changes in the working capital, given the recovery in Brent crude oil prices in 2QFY16, which is expected to lead to higher inventory values.

Stock Not Overvalued

“We do not view Cabot shares as overvalued, given that they are capable of generating a ~6% free cash flow yield in 2016. We note, however, that higher free cash flow yields can be captured with Minerals Technologies shares or Orion Engineered Carbons,” the analyst added.

Latest Ratings for CBT

Oct 2019DowngradesOutperformNeutral
Oct 2019Initiates Coverage OnNeutral
Aug 2019MaintainsOverweight

View More Analyst Ratings for CBT
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Downgrades Price Target Commodities Markets Analyst Ratings Trading Ideas


Related Articles (CBT)

View Comments and Join the Discussion!

Benzinga's Volume Movers

Stocks Hitting 52-Week Lows